针对大 RNA 载荷与组织靶向优化的脂质纳米颗粒增强体内基因组编辑
Lipid nanoparticles optimized for large RNA cargo and tissue targeting enhance in vivo genome editing
一项研究对脂质纳米颗粒(LNP)进行优化,以装载大尺寸 RNA 载荷并实现组织靶向,从而提升体内基因组编辑效果。该工作聚焦 LNP 递送大 RNA 货物与组织选择性这一递送瓶颈,属于递送载体层面的研究进展,尚处实验研究阶段。
Villiger, L. et al. CRISPR technologies for genome, epigenome and transcriptome editing. Nat. Rev. Mol. Cell Biol. 25, 464–487 (2024).
Pacesa, M., Pelea, O. & Jinek, M. Past, present, and future of CRISPR genome editing technologies. Cell 187, 1076–1100 (2024).
Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 533, 420–424 (2016).
Gaudelli, N. M. et al. Programmable base editing of A•T to G•C in genomic DNA without DNA cleavage. Nature 551, 464–471 (2017).
Chemello, F., Olson, E. N. & Bassel-Duby, R. CRISPR-editing therapy for Duchenne muscular dystrophy. Hum. Gene. Ther. 34, 379–387 (2023).
Xu, W., Zhang, S., Qin, H. & Yao, K. From bench to bedside: cutting-edge applications of base editing and prime editing in precision medicine. J. Transl. Med. 22, 1133 (2024).
Leonard, A. & Tisdale, J. F. A new frontier: FDA approvals for gene therapy in sickle cell disease. Mol. Ther. 32, 264–267 (2024).
Raguram, A., Banskota, S. & Liu, D. R. Therapeutic in vivo delivery of gene editing agents. Cell 185, 2806–2827 (2022).
Bulcha, J. T., Wang, Y., Ma, H., Tai, P. W. L. & Gao, G. Viral vector platforms within the gene therapy landscape. Signal Transduct. Target. Ther. 6, 53 (2021).
Hanlon, K. S. et al. High levels of AAV vector integration into CRISPR-induced DNA breaks. Nat. Commun. 10, 4439 (2019).
Doman, J. L., Raguram, A., Newby, G. A. & Liu, D. R. Evaluation and minimization of Cas9-independent off-target DNA editing by cytosine base editors. Nat. Biotechnol. 38, 620–628 (2020).
Charlesworth, C. T. et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat. Med. 25, 249–254 (2019).
Dong, B., Nakai, H. & Xiao, W. Characterization of genome integrity for oversized recombinant AAV vector. Mol. Ther. 18, 87–92 (2010).
Ryu, S. M. et al. Adenine base editing in mouse embryos and an adult mouse model of Duchenne muscular dystrophy. Nat. Biotechnol. 36, 536–539 (2018).
Truong, D. J. et al. Development of an intein-mediated split-Cas9 system for gene therapy. Nucleic Acids Res. 43, 6450–6458 (2015).
Kohn, D. B., Chen, Y. Y. & Spencer, M. J. Successes and challenges in clinical gene therapy. Gene Ther. 30, 738–746 (2023).
Tsuchida, C. A., Wasko, K. M., Hamilton, J. R. & Doudna, J. A. Targeted nonviral delivery of genome editors in vivo. Proc. Natl Acad. Sci. USA 121, e2307796121 (2024).
Hou, X., Zaks, T., Langer, R. & Dong, Y. Lipid nanoparticles for mRNA delivery. Nat. Rev. Mater. 6, 1078–1094 (2021).
Adams, D. et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N. Engl. J. Med. 379, 11–21 (2018).
Polack, F. et al. Safety and Efficacy of the BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
Baden, L. indsey et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
Kazemian, P. et al. Lipid-nanoparticle-based delivery of CRISPR/Cas9 genome-editing components. Mol. Pharm. 19, 1669–1686 (2022).
Gillmore, J. ulian et al. Nexiguran ziclumeran gene editing in hereditary ATTR with polyneuropathy. N. Engl. J. Med. 393, 1375–1386 (2025).
Zheng, L., Bandara, S. R., Tan, Z. & Leal, C. Lipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm. Proc. Natl Acad. Sci. USA 120, e2301067120 (2023).
Garaizar, A. et al. Toward understanding lipid reorganization in RNA lipid nanoparticles in acidic environments. Proc. Natl Acad. Sci. USA 121, e2404555121 (2024).
Chatterjee, S., Kon, E., Sharma, P. & Peer, D. Endosomal escape: a bottleneck for LNP-mediated therapeutics. Proc. Natl Acad. Sci. USA 121, e2307800120 (2024).
Ly, H. H., Daniel, S., Soriano, S. K. V., Kis, Z. & Blakney, A. K. Optimization of lipid nanoparticles for saRNA expression and cellular activation using a design-of-experiment approach. Mol. Pharm. 19, 1892–1905 (2022).
Hald Albertsen, C. et al. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv. Drug Deliv. Rev. 188, 114416 (2022).
Li, B. et al. Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing. Nat. Biotechnol. 41, 1410–1415 (2023).
Chen, J. et al. Combinatorial design of ionizable lipid nanoparticles for muscle-selective mRNA delivery with minimized off-target effects. Proc. Natl Acad. Sci. USA 120, e2309472120 (2023).
Xu, Y. et al. Rational design and modular synthesis of biodegradable ionizable lipids via the Passerini reaction for mRNA delivery. Proc. Natl Acad. Sci. USA 122, e2409572122 (2025).
Miao, L. et al. Delivery of mRNA vaccines with heterocyclic lipids increases anti-tumor efficacy by STING-mediated immune cell activation. Nat. Biotechnol. 37, 1174–1185 (2019).
Madisen, L. et al. A robust and high-throughput Cre reporting and characterization system for the whole mouse brain. Nat. Neurosci. 13, 133–140 (2010).
Yu, S. Y. et al. A luciferase reporter mouse model to optimize in vivo gene editing validated by lipid nanoparticle delivery of adenine base editors. Mol. Ther. 31, 1159–1166 (2023).
Wolter, J. M. et al. Cas9 gene therapy for Angelman syndrome traps Ube3a-ATS long non-coding RNA. Nature 587, 281–284 (2020).
Buiting, K., Williams, C. & Horsthemke, B. Angelman syndrome—insights into a rare neurogenetic disorder. Nat. Rev. Neurol. 12, 584–593 (2016).
Binici, B., Rattray, Z., Zinger, A. & Perrie, Y. Exploring the impact of commonly used ionizable and pegylated lipids on mRNA-LNPs: a combined in vitro and preclinical perspective. J. Control. Release 377, 162–173 (2025).
Cheng, M. H. Y. et al. Liposomal lipid nanoparticles for extrahepatic delivery of mRNA. Nat. Commun. 16, 4135 (2025).
Musunuru, K. et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593, 429–434 (2021).
Reiber, H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin. Chim. Acta 310, 173–186 (2001).
Xue, Y. et al. Lipid nanoparticles enhance mRNA delivery to the central nervous system upon intrathecal injection. Adv. Mater. 37, 2417097 (2025).
Cao, D. et al. Lipid nanoparticles for mRNA delivery in brain via systemic administration. Sci. Adv. 11, eadw0730 (2025).
Kim, J., Eygeris, Y., Ryals, R. C., Jozić, A. & Sahay, G. Strategies for non-viral vectors targeting organs beyond the liver. Nat. Nanotechnol. 19, 428–447 (2024).
Loughrey, D. & Dahlman, J. E. Non-liver mRNA delivery. Acc. Chem. Res. 55, 13–23 (2022).
Bentz, J., Ellens, H., Lai, M. Z. & Szoka, F. C. On the correlation between HII phase and the contact-induced destabilization of phosphatidylethanolamine-containing membranes. Proc. Natl Acad. Sci. USA 82, 5742–5745 (1985).
Bao, X. et al. Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): from bench to bedside. Signal Transduct. Target. Ther. 9, 13 (2024).
Vendrely, K. M., Kumar, S., Li, X. & Vaughan, A. M. Humanized mice and the rebirth of malaria genetic crosses. Trends Parasitol. 36, 850–863 (2020).
Stone, D. et al. Serum factors create species-specific barriers to hepatic gene transfer by lipid nanoparticles in liver-humanized mice. Mol. Ther. Methods Clin. Dev. 33, 101470 (2025).
Sun, Y. et al. In vivo editing of lung stem cells for durable gene correction in mice. Science 384, 1196–1202 (2024).
Dong, S. et al. A modular mRNA platform for programmable induction of tumour-specific immunogenic cell death. Nat. Nanotechnol. 20, 1856–1870 (2025).
Marks, A. et al. mRNA vaccine immunity is enhanced by hepatocyte detargeting and not dependent on dendritic cell expression. Nat. Biotechnol. https://doi.org/10.1038/s41587-026-03099-z (2026).
Liu, C. et al. mRNA-based cancer therapeutics. Nat. Rev. Cancer 23, 526–543 (2023).
Qin, S. et al. mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduct. Target. Ther. 7, 166 (2022).
Lian, X. et al. Bone-marrow-homing lipid nanoparticles for genome editing in diseased and malignant haematopoietic stem cells. Nat. Nanotechnol. 19, 1409–1417 (2024).
Xue, L. et al. Combinatorial design of siloxane-incorporated lipid nanoparticles augments intracellular processing for tissue-specific mRNA therapeutic delivery. Nat. Nanotechnol. 20, 132–143 (2025).
Xu, Y. et al. AGILE platform: a deep learning powered approach to accelerate LNP development for mRNA delivery. Nat. Commun. 15, 6305 (2024).
Wang, C. et al. Blood–brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system. Nat. Mater. 24, 1653–1663 (2025).
Dong, S. et al. Biodegradable lipid nanoparticles for genome editing in the brain via intrathecal administration. Mater. Today 92, 140–150 (2026).
Gong, F. et al. Amino acid-derived ionizable lipids enable inhaled base editing for therapeutic gene correction in the lung. Nat. Mater. https://doi.org/10.1038/s41563-026-02555-0 (2026).
Schlich, M. et al. Cytosolic delivery of nucleic acids: the case of ionizable lipid nanoparticles. Bioeng. Transl. Med. 6, e10213 (2021).
Álvarez-Benedicto, E. et al. Optimization of phospholipid chemistry for improved lipid nanoparticle (LNP) delivery of messenger RNA (mRNA). Biomater. Sci. 10, 549–559 (2022).
Gruner, S. M., Cullis, P., Hope, M. & Tilcock, C. Lipid polymorphism: the molecular basis of nonbilayer phases. Annu. Rev. Biophys. Biophys. Chem. 14, 211–238 (1985).
Frolov, V. A., Shnyrova, A. V. & Zimmerberg, J. Lipid polymorphisms and membrane shape. Cold Spring Harb. Perspect. Biol. 3, a004747 (2011).
Kobierski, J., Wnętrzak, A., Chachaj-Brekiesz, A. & Dynarowicz-Latka, P. Predicting the packing parameter for lipids in monolayers with the use of molecular dynamics. Colloids Surf. B 211, 112298 (2022).
Hurley, A. & Lagor, W. R. Treating cardiovascular disease with liver genome engineering. Curr. Atheroscler. Rep. 24, 75–84 (2022).
Pankowicz, F. P. et al. Reprogramming metabolic pathways in vivo with CRISPR/Cas9 genome editing to treat hereditary tyrosinaemia. Nat. Commun. 7, 12642 (2016).
Rothgangl, T. et al. In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. Nat. Biotechnol. 39, 949–957 (2021).
Ferrari, S., Geddes, D. M. & Alton, E. W. F. W. Barriers to and new approaches for gene therapy and gene delivery in cystic fibrosis. Adv. Drug Deliv. Rev. 54, 1373–1393 (2002).
Ramalho, A. S. et al. Five percent of normal cystic fibrosis transmembrane conductance regulator mRNA ameliorates the severity of pulmonary disease in cystic fibrosis. Am. J. Respir. Cell Mol. Biol. 27, 619–627 (2002).
Alapati, D. & Morrisey, E. E. Gene editing and genetic lung disease. Basic research meets therapeutic application. Am. J. Respir. Cell Mol. Biol. 56, 283–290 (2017).
Anzalone, A. V. et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 576, 149–157 (2019).
Fell, C. W. et al. Reprogramming site-specific retrotransposon activity to new DNA sites. Nature 642, 1080–1089 (2025).
Chen, Y. et al. All-RNA-mediated targeted gene integration in mammalian cells with rationally engineered R2 retrotransposons. Cell 187, 4674–4689 (2024).
Kluesner, M. G. et al. EditR: a method to quantify base editing from Sanger sequencing. CRISPR J. 1, 239–250 (2018).
Brinkman, E. K., Chen, T., Amendola, M. & van Steensel, B. Easy quantitative assessment of genome editing by sequence trace decomposition. Nucleic Acids Res. 42, e168 (2014).
来源:Nature Biotechnology · nature.com